62 results about "Endothelial proliferation" patented technology

The invention provides methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.

Compositions and methods effective in inhibiting abnormal or undesirable cell proliferation, particularly endothelial cell proliferation and angiogenesis related to neovascularization and tumor growth are provided. The compositions comprise peptide molecules, optionally containing one or more individual peptide chains covalently linked, and optionally modified with polyethylene glycol (PEG). The methods involve administering to a human or animal the composition described herein in a dosage sufficient to inhibit cell proliferation, particularly endothelial cell proliferation. The methods are useful for treating diseases and processes mediated by undesired and uncontrolled cell proliferation, such as cancer, particularly by inhibiting angiogenesis. Administration of the composition to a human or animal having prevascularized, metastasized tumors is useful for preventing the growth or expansion of such tumors.

The invention relates to proteins comprising angiogenesis inhibiting peptides, such as endostatin peptides (including, but not limited to, fragments and variants thereof), which exhibit anti-retroviral activity, fused or conjugated to albumin (including, but not limited to fragments or variants of albumin). These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins exhibit extended shelf-life and / or extended or therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acuds, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and / or host cells. The invention also relates to compositions and methods for inhibiting proliferation of vascular endothelial cells and tumor aniogenesis induced cell fusion. The invention further relates to compositions and methods preventing growth of, or promoting regression of, primary tumors and metastases; and for treating cancer, diabetic retinophathy, progressive macular degeneration or rheumatoid arthritis.

The present invention concerns an antibody or fragment thereof, capable of binding to CD 160, said antibody comprising a) a light chain comprising three light chain complementary regions (CDRs) having the following amino acid sequences: (i) the light chain CDR1: QSISNH (SEQ ID NO: 1), (ii) the light chain CDR2: YAS, (iii) the light chain CDR3: QQSNSWPLT (SEQ ID NO: 2), and a light chain framework sequence from an immunoglobulin light chain; and b) a heavy chain comprising three heavy chain complementary regions (CDRs) having the following amino acid sequences: (i) the heavy chain CDR1: GYTFTDYW (SEQ ID NO: 3), (ii) the heavy chain CDR2: IYPGDDDA (SEQ ID NO: 4); (iii) the heavy chain CDR3: ARRGIAAVVGGFDY (SEQ ID NO: 5); and a heavy chain framework sequence from an immunoglobulin heavy chain; a pharmaceutical comprising said antibody and the use of said antibody for preparation of a medicament for treating and / or preventing a pathology associated with endothelial cells proliferation engaged in an angiogenesis process.

The invention belongs to the field of antibody drug, and discloses a full human-derived anti-human VEGFR2 monoclonal antibody screened by a phage antibody base technology and prepared by a gene engineering method, and further discloses a carrier including polynucleotide for encoding the monoclonal antibody, a host cell and an application. Through combining with VEGFR2, the monoclonal antibody stops the combination of VEGF with VEGR2, and does not induce receptor dimerization, cause the following tyrosine residue phosphorylation in intracellular tyrosine kinase structure and activate downstream signal access including activation of phospholipase C and increase of calcium ion concentration in the cell and others; the antibody drug triggers endothelial proliferation, survival, cytoskeleton rearrangement, cell migration, gene expression and others, and finally stops the vascular proliferation caused by combination of VEGF and VEGFR2 and induction of dimerization. The monoclonal antibody can be used for treating diseases caused by tumor angiogenesis.

The invention belongs to gene engineering field. The invention establish a production method of human skeletal muscle troponin I for quick contract: recombing DNA to construct expression plasmid, refining expression products with inclusion bodies, cation exchange resin column chromatography, cation exchange resin column chromatography, renaturing inclusion bodies, at last purifying and obtaining recombinant human troponin I for suppressing blood vessel endothelial cell propagation and angiogenesis. The invention also establishes a method for determing the biological activity index of troponin I by suppressing Acto-S1 Mg-ATPase activity. The troponin I can prepare drugs of the tumor and angiogenesis related disease

The invention relates to application of Metrnl protein or gene in treatment of endothelial function impairment. On one hand, based on a Metrnl endothelial specific knockout mouse model, it is proved that due to lacking of Metrnl in blood vessel endothelia, an endothelium-dependent relaxation function is lowered, while Metrnl has the function of dilating blood vessels; on the other hand, based on a human umbilical vein endothelial cell line and Metrnl endothelial specific knockout mouse primary endothelial cells, it is proved that the cell proliferation is lowered after knockout of blood vessel endothelia Metrnl, showing that Metrnl has the effect of promoting endothelial cell proliferation. Therefore, the Metrnl protein or gene and a synergist of the Metrnl protein or gene can be used for preparing reagents for treating endothelium-dependent blood vessel relaxation dysfunction or regulating endothelial cell proliferation, and are applied to development of drugs of diseases related to endothelial function impariment.

The present invention provides an in vitro method for identifying a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and / or endothelial cell proliferation for the manufacture of a diagnostic or therapeutic agent. The present invention further provides the identified compounds and pharmaceutical compositions, and assays and kits for identifying a compound or using a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and / or endothelial cell proliferation and is useful for bioprinting.

Provided herein is a method for inducing formation of a conformationally distinct superfibronectin by contacting plasma fibronectin with BBK32 protein or a BBK32 peptide and the BBK32-induced superfibronectin so formed. Also provided are methods of inhibiting endothelial cell proliferation, of treating pathophysiological conditions associated with endothelial cell proliferation and of inhibiting angiogenesis therein using the BBK32 protein, BBK32 peptide or the BBK32-induced superfibronectin.

Murine and humanized anti-human VEGF antibodies and uses are disclosed. The anti-human VEGF antibodies of the invention have higher binding affinity for human VEGF-A, are stronger inhibitors of the VEGF-A induced proliferation of endothelial cells in culture as compared with anti-human VEGF antibodies in the art. Moreover, these antibodies cross react with human VEGF-B. The antibodies of the invention inhibit tumor growth in vivo in greater extent than Bevacizumab (Avastin™) when administered at the same dosage

The invention relates to a traditional Chinese medicine patch for the prevention and early-stage curing of bronchial asthma, and the treatment of a plurality of respiratory diseases and megrims, characterized in that the traditional Chinese medicine patch comprises, based on the weight percentage, 57 to 70 % of peach seed, 12 to 25 % of cape jasmine, 6 to 8 % of almond, and 5 to 10% of pepper. The invention has the advantages that the traditional Chinese medicine patch is mainly used for treating bronchial asthma, can cure the bronchial asthma of children at the age of below 12, and can be used in the outbreaking or catabatic period. The traditional Chinese medicine patch has the efficacy of diminishing inflammation, invigorating blood circulation, removing blood stasis, clearing away cold, relieving cough and calming panting. The traditional Chinese medicine patch can promote the synthesis of the alveolar surfactant, protect the pulmonary function to improve the lesion tissues, and can stimulate the proliferation of blood vessel endothelial cells to restore the endangium. The traditional Chinese medicine patch has the antiallergic effect, can inhibit the antiserum reaction of allergic antibody of the skin, reduce the pigment seepage and alleviate the airway obstruction. The traditional Chinese medicine patch can enhance the proliferation and conversion of T lymphocyte of spleen of a body, and improve the autoimmunity.

The invention discloses a substituted 2,3-dihydro-4(1H)- quinazolone derivative shown in the formula I, pharmaceutically acceptable salt or solvate and a drug composite containing the same and application thereof. The compound has very good effect of restraining vascular endothelial cell proliferation. The compound, the pharmaceutically acceptable salt or solvate or the drug composite containing the same can be used for drugs requiring to restraining angiogenesis diseases and / or cytotoxicity exerting diseases.

AT4 receptor agonists are potent activators of angiogenesis and can be used to treat diseases that are characterized by vascular insufficiency. AT4 receptor antagonists, which are potent inhibitors of angiogenesis, and can be used as anti-angiogenic agents for the treatment of cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerotic plaque formation, and any disease process that is characterized by excessive, undesired or inappropriate angiogenesis or proliferation of endothelial cells.

The invention relates to a method for preparing for taspine alkali and the applied in preparing for the drug to treat tumor. The preparing method comprises: preparing for dissolving solution, dissolving the cohosh root base, adsorption stripping, preparing for eluent, cleaning, and concave condensation, recrystallizing and checking. The 222 test result expresses that it has the effect of depressing blood vessel formation.

Embodiments of the invention provide methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, as well as attenuating cancerous tumor growth and metastasis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.

The invention discloses modified recombinant human endostatin and an application thereof. The modified recombinant human endostatin has the following structure: CH3O-(CH2CH2O)m-CH2CH2CH2-N<alpha>H-Endosta, wherein the weight average molecular weight of CH3O-(CH2CH2O)m-CH2CH2CH2- is between 20 and 40Kd. The modified recombinant human endostatin strengthens in vivo stability, improves plasma concentration, prolongs half decay period, and remarkably increases the proliferative activity of anti-endothelial cells, thereby reducing administration dosage, reducing administration frequency, and relieving the body pain and the economical burden of patients. The modified recombinant human endostatin can be used to prepare antineoplastic medicine.

AT4 receptor agonists are potent activators of angiogenesis and can be used to treat diseases that are characterized by vascular insufficiency. AT4 receptor antagonists, which are potent inhibitors of angiogenesis, and can be used as anti-angiogenic agents for the treatment of cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerotic plaque formation, and any disease process that is characterized by excessive, undesired or inappropriate angiogenesis or proliferation of endothelial cells.

The invention belongs to the field of gene engineering, which relates to an Endothelin resistant (esoderma cytostatic agent), its encoding gene and use in preparing medicament for resisting rumor blood vessel production, wherein the esoderma cytostatic agent is screened from No1-89 amino acid fragment of the recombined human collagen IV alpha 2 chain NC1 region, the esoderma cytostatic agent possesses the action of suppressing endocytosis breeding, and can be used in preparing medicament for suppressing blood vessel generation.

A DNA composition effective for inhibiting endothelial cell proliferation comprises a DNA construct operably encoding a vascular endothelial growth factor (VEGF) receptor polypeptide, which can be a full length VEGF receptor protein or an immunogenic fragment thereof. This invention provides DNA compositions that encode VEGF receptor-2 (KDR), VEGF receptor-1 (Flt-1), or Flk-1 (the murine homolog of KDR), as well as methods of using such a DNA composition to inhibit vascular endothelial cell proliferation in the tumor micro-environment. Angiogenesis inhibition and subsequent decrease in tumor growth and dissemination is achieved.

The invention discloses a molecular marker for early warning of atherosclerosis. A method comprises the following steps that (1) the influence of Hcy (Homocysteine) with different concentrations on endothelial cell proliferation is detected by an MTT colorimetric method, and a proper concentration is screened out; (2) after cells is intervened with the Hcy with optimal concentration, cell viability staining detection is carried out; (3) after the cells is intervened with the Hcy with optimal concentration, the apoptosis of endothelial cells is detected by flow cytometry; (4) after the cells isintervened with the Hcy with optimal concentration, the expression of LncRNA (long noncoding RNA) DINO (Damage Induced Noncoding) is detected through fluorescent quantitative PCR in real time; (5) transfecting of the LncRNA DINO siRNA is carried out, after the LncRNA DINO is interfered, and then cell viability staining detection is carried out; (6) LncRNA DINO siRNA is constructed, after the LncRNA DINO is interfered, and the apoptosis of endothelial cells is detected by flow cytometry; and (7) LncRNA DINO siRNA is constructed, after the LncRNA DINO is interfered, and then the expression of apoptosis-related protein is detected by protein immunoblotting. A novel molecular target for early diagnosis and early warning of atherosclerosis is provided, and a new direction is provided for treatment.

The invention relates to a heparin-loaded covered stent for treating arterial aneurysm and a preparation method thereof. The covered stent is characterized in that a covered layer is formed by heparin-loaded emulsion electrostatic spinning nanofibers, wherein the heparin-loaded nanofibers are provided with multi-core-layer structures. The preparation method of the covered stent comprises the following steps of arranging a preparation device, compounding a heparin sodium aqueous solution, preparing heparin sodium aqueous solution-sorbide oleate-dichloromethane emulsion, preparing an electrostatic spinning solution, and preparing a loading heparin covered stent. By adopting the covered stent, the problems which are common in treatment of small vessel diseases such as vascular endothelial proliferation and thrombosis can be effectively avoided; the heparin-loaded covered stent has a wide application prospect in the field of intravascular interventional treatment of small vessels arterial aneurysm; and the preparation method has the advantages that the preparation device is simple, procedure parameters are less, and the preparation process is stable.

Compositions and methods effective in inhibiting abnormal or undesirable cell proliferation, particularly endothelial cell proliferation and angiogenesis related to neovascularization and tumor growth are provided. The compositions comprise a naturally occurring or synthetic protein, peptide, or protein fragment containing all or an active portion of the C-terminal portion of proteinase inhibitors such as TFPI. The methods involve administering to a human or animal the composition described herein in a dosage sufficient to inhibit cell proliferation, particularly endothelial cell proliferation. The methods are useful for treating diseases and processes mediated by undesired and uncontrolled cell proliferation, such as cancer, particularly by inhibiting angiogenesis. Administration of the composition to a human or animal having prevascularized, metastasized tumors is useful for preventing the growth or expansion of such tumors.

The invention provides a multifunctional aerogel dressing for promoting wound healing and a preparation method thereof. The preparation method of the multifunctional aerogel dressing comprises the following steps that S1, an amino acid derivative, an antibacterial polypeptide derivative and natural polysaccharide are dispersed in deionized water, and a clear solution is obtained after heating; S2,the clear solution containing the amino acid derivative, the antibacterial polypeptide derivative and the natural polysaccharide is guided into into a mold, and cooling is performed to room temperature to form hydrogel; and S3, the hydrogel is subjected to freeze drying, and the multifunctional aerogel dressing is prepared. The invention provides the multifunctional wound dressing material capable of promoting proliferation of skin fibroblasts and endothelial cells, resisting bacteria in a broad spectrum and absorbing exudate and the preparation method of the multifunctional wound dressing material. The problems that an existing wound dressing is single in function and cannot effectively promote wound healing and prevent wound infection are solved.

Murine and humanized anti-human VEGF antibodies and uses are disclosed. The anti-human VEGF antibodies of the invention have higher binding affinity for human VEGF-A, are stronger inhibitors of the VEGF-A induced proliferation of endothelial cells in culture as compared with anti-human VEGF antibodies in the art. Moreover, these antibodies cross react with human VEGF-B. The antibodies of the invention inhibit tumor growth in vivo in greater extent than Bevacizumab when administered at the same dosage.

The present invention relates to a method for expression and purification of human troponin C(TnC) and its application using said protein as medicine for resisting angiogenesis. It adopts PCR method,and includes the following steps: obtaining coded sequence of human troponin C from human mammary gland cDNA library; constructing colibacillus expression plasmid containing said coded sequence, pET36-TnC and its transformed colibacillus engineering bacterium strain E. coli BL21(DE3)pLyS / pET36-TnC; and utilizing said engineering bacterium expression to produce human troponin C with biological activity white can inhibit vascular endothelial proliferation and inhibit tumor growth. It can be used as medicine for curing tumor.

The invention relates to a heparin-loaded covered stent for treating arterial aneurysm and a preparation method thereof. The covered stent is characterized in that a covered layer is formed by heparin-loaded emulsion electrostatic spinning nanofibers, wherein the heparin-loaded nanofibers are provided with multi-core-layer structures. The preparation method of the covered stent comprises the following steps of arranging a preparation device, compounding a heparin sodium aqueous solution, preparing heparin sodium aqueous solution-sorbide oleate-dichloromethane emulsion, preparing an electrostatic spinning solution, and preparing a loading heparin covered stent. By adopting the covered stent, the problems which are common in treatment of small vessel diseases such as vascular endothelial proliferation and thrombosis can be effectively avoided; the heparin-loaded covered stent has a wide application prospect in the field of intravascular interventional treatment of small vessels arterial aneurysm; and the preparation method has the advantages that the preparation device is simple, procedure parameters are less, and the preparation process is stable.

Stable water soluble polypeptides which are potent inhibitors of endothelial cell proliferation and of angiogenesis. Polypeptide inhibitors of endothelial cell growth may have important uses in the elucidation of the mechanism of angiogenesis, disease diagnosis and prognostication, and drug therapies for use in animals and humans.

The invention discloses a cortex albiziae lignan glycoside compound promoting endothelial cell proliferation and application, and belongs to the technical field of biomedicine. New application of Icarisid E5 in promoting the proliferation and migration of endothelial cells and promoting angiogenesis is provided. It is confirmed by experiments that the HUVEC cell viability after administration of 40 [mu]M for 24 h can be increased to 133.65% of the control, cell migration can be significantly promoted, and the function of promoting wound healing in in-vivo experiments is achieved. The preparedmonomeric compound Icarisid E5 can significantly promote cell proliferation activity, promote the migration and self-replication of HUVEC cells, can be used for transferring exogenous angiogenesis-inducing factors into tissue, promotes angiogenesis, and enhances cell reproductive capacity.

The invention discloses a hydrolysis plasminogen polypeptide and an application thereof, relates to the field of medicine, and in particular to the polypeptide capable of promoting plasminogen to hydrolyze to be angiostatin and capable of curing cancer. The sequence EMQKTVDRLKALNHFDENMW of the polypeptide is a brand new sequence. The plasminogen can be promoted to hydrolyze outside a mice body, vascular endothelial cells are restrained to proliferate, the survival rate of tumor-bearing mice can be improved in vivo test, and the hydrolysis plasminogen polypeptide and the application thereof have potential developing value for the new medicine.

The invention relates to the medicine field, in particular to polypeptide capable of promoting profibrinolysin to be hydrolyzed into angiostain and treating a malignant tumor. The sequence of the polypeptide is THELGHLSQKLYGKRSN and is a brand new sequence, the polypeptide can promote the hydrolyzation of the profibrinolysin in vitro and inhibit the proliferation of vascular endothelial cells, in a vivo test, the survival rate of tumor-bearing mice is improved, and the polypeptide has a potential new drug development value.